Teligent, Inc. (TLGT) Stock Rating Upgraded by Zacks Investment Research
Teligent, Inc. (NASDAQ:TLGT) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. “
Other equities analysts have also recently issued reports about the company. Canaccord Genuity restated a “buy” rating and set a $11.00 target price on shares of Teligent in a report on Tuesday, August 8th. Roth Capital set a $9.00 price target on Teligent and gave the company a “buy” rating in a research report on Wednesday, August 9th. BidaskClub lowered Teligent from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. ValuEngine lowered Teligent from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. Finally, Deutsche Bank AG reduced their price target on Teligent from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Teligent has an average rating of “Hold” and an average price target of $9.33.
Shares of Teligent (NASDAQ:TLGT) opened at 6.88 on Friday. The company has a 50 day moving average price of $6.92 and a 200 day moving average price of $6.92. The company’s market capitalization is $367.33 million. Teligent has a 12-month low of $5.74 and a 12-month high of $9.54.
Teligent (NASDAQ:TLGT) last announced its earnings results on Tuesday, August 8th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The firm had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $20.11 million. During the same quarter last year, the business earned $0.02 earnings per share. The business’s revenue was up 7.4% compared to the same quarter last year. Equities analysts anticipate that Teligent will post $0.07 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its position in shares of Teligent by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 49,622 shares of the company’s stock worth $454,000 after acquiring an additional 200 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Teligent by 1.0% during the 4th quarter. Teachers Advisors LLC now owns 65,454 shares of the company’s stock worth $433,000 after acquiring an additional 648 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Teligent by 3.1% during the 1st quarter. Wells Fargo & Company MN now owns 45,617 shares of the company’s stock worth $357,000 after acquiring an additional 1,369 shares in the last quarter. American International Group Inc. raised its position in shares of Teligent by 7.1% during the 1st quarter. American International Group Inc. now owns 25,488 shares of the company’s stock worth $199,000 after acquiring an additional 1,680 shares in the last quarter. Finally, Voya Investment Management LLC raised its position in shares of Teligent by 16.1% during the 2nd quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock worth $214,000 after acquiring an additional 3,234 shares in the last quarter. 66.00% of the stock is currently owned by institutional investors and hedge funds.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.